scholarly journals Tumor Size as a Critical Prognostic Factor in T1-2 Stage Esophageal Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Zilong Wu ◽  
Bentong Yu
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Tumor Size ◽  
Cox Model ◽  
Clinical Stage ◽  
Discriminative Ability ◽  
Tnm System ◽  
Model Based ◽  
T Stage

Background. Tumor size has been measured in esophageal cancer for decades, but the role of tumor size in relation to T stage in the prediction of survival is still underappreciated. Thus, the present study is aimed at investigating the influence of T stage on the predictive value of tumor size in clinical stage I–IV esophageal cancer patients. Materials and Methods. Data were obtained from the Surveillance, Epidemiology, and End Results Program (SEER) cancer registry program. Cox proportional hazards regression was utilized to identify the independent prognostic ability of the factor. Kaplan-Meier analysis was used to estimate the distribution of survival outcome. Harrell’s concordance index (c-index) was used to quantify the predictive ability of the prognostic model and prognostic factor. Results. According to the T stage, subgroup analysis showed that tumor size was not an independent risk factor in T3 and T4 stage esophageal cancer patients. Furthermore, the predictive power of tumor size was negatively impacted by the increase in T stage. Furthermore, the discriminative ability of the Cox model based on the tumor-node-metastasis (TNM) system with tumor size outperformed the model based on the TNM system only. Conclusion. The current study identified tumor size as a critical clinical prognostic signature for esophageal cancer with considerable discriminatory ability and prognostic value. Therefore, tumor size should be included in the American Joint Committee on Cancer (AJCC) TNM staging of T1-2 esophagus cancer patients.

MON-PP199: Immunonutritional Prognostic Factor and Oral Status After Neoadjuvant Chemotherapy in Esophageal Cancer Patients

2015 ◽  
Vol 34 ◽  
pp. S202
Author(s):  
R. Yamanaka ◽  
M. Inoue-Minakuchi ◽  
Y. Soga ◽  
A. Yokoi ◽  
M. Shimura ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factor ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients

ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients

2020 ◽  
Vol 27 (S3) ◽  
pp. 886-887
Author(s):  
Satoru Matsuda ◽  
Hiroya Takeuchi ◽  
Hirofumi Kawakubo ◽  
Ryo Takemura ◽  
Yusuke Maeda ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Treatment Strategy

Preoperative factors predictive of pathologic upstaging in clinical stage I gastric cancer patients.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 39-39
Author(s):  
Hayavadhan Thuppal ◽  
Patricia Friedmann ◽  
John Christopher McAuliffe ◽  
Peter Muscarella ◽  
Haejin In
Keyword(s):  
Risk Factors ◽  
Gastric Cancer ◽  
Logistic Regression ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Tumor Size ◽  
Lymphovascular Invasion ◽  
Clinical Stage ◽  
Gastric Cancer Patients ◽  
Stage 1

39 Background: In patients with stage 1 gastric cancer, surgical resection without neoadjuvant therapy is offered as the first line treatment. However, some of these patients are found to have higher stage after resection and miss the opportunity for neoadjuvant therapy. Preoperative patient and tumor characteristics may be predictive of the likelihood of pathological upstaging in stage 1 gastric cancer patients who have not received neo-adjuvant therapy. Methods: The National Cancer Database was queried for patients diagnosed from 2004-2015 with clinical stage 1 gastric adenocarcinoma who had undergone surgical resection without neoadjuvant therapy. Univariate analysis and multivariable logistic regression were conducted to determine pre-operative factors associated with pathological upstaging. Candidate variables examined included age, sex, race, tumor size, histology, grade, tumor location, days to surgery, and lymphovascular invasion. Results: Analysis was conducted on 8,015 clinical stage 1 patients. Overall 1,981 (25%) patients were upstaged. On multivariable logistic regression analysis, significant predictors of upstaging included increasing tumor size [ref : size < 1 cm, 1-2 cm aOR=3.8 (95% CI 2.3-6.1); 2-4 cm aOR=12.4 (7.9-19.5); > = 4cm aOR=25.9 (22.9-56.4)], younger age [ref: > = 75, < 50 aOR=1.7 (1.4-2.1), 50-65 aOR=1.4 (1.2-1.6), 65-75 aOR=1.2 (1.1-1.5)], male gender [aOR=1.16 (1.0-1.3)], presence of diffuse type gastric cancer [aOR=2.3 (1.7-3.2)], mucinous type [aOR=1.7 (1.1-2.5)], or signet ring cell histology [aOR=1.6 (1.3-2.0)] compared to intestinal histology, presence of lymphovascular invasion [aOR=6.0 (5.0-7.1)], and increasing grade [ref: grade 1, grade 2 aOR=2.30 (1.7-3.5); grade 3 aOR=4.9 (3.6- 6.7)]. Conclusions: A quarter of all patients thought to have stage 1 gastric cancer prior to surgery had higher pathologic stage at time of resection. Patients with the above risk factors may be understaged with currently available diagnostic tools. The addition of neoadjuvant therapy should be considered when the above risk factors are present in clinical stage 1 patients.

scholarly journals MODERN METHODS OF DIAGNOSIS OF MAMMARY TUMOR AND TUMOR-LIKE LESIONS IN CATS

THE BULLETIN ◽  
2021 ◽  
Vol 3 (391) ◽  
pp. 33-39
Author(s):  
G.P. Dyulger ◽  
P.G. Dyulger ◽  
O. Alikhanov ◽  
E.S. Latynina ◽  
D.A. Baimukanov
Keyword(s):  
Prognostic Factors ◽  
Growth Factor ◽  
Lymph Nodes ◽  
Tumor Cells ◽  
Tumor Size ◽  
Clinical Stage ◽  
Distant Metastases ◽  
Regional Lymph Nodes ◽  
Tnm System ◽  
High Level

The paper provides an overview of the classification and diagnosis of feline mammary tumors (FMT) in cats. The clinical stage of neoplastic process is one of the driving prognostic factors. In accordance with the WHO recommendations 1980, it is determined by the TNM system: the size of neoplasm, the state of regional lymph nodes and the presence/absence of distant metastases. The clinical stage of the disease is defined based on the obtained data during the examination, surgery and study of the postoperative material (excised tumor, the edges of the resection and regional lymph nodes). It was found that tumors larger than 3 cm have a significantly worse prognosis than tumors smaller than 3 cm. The median survival with a tumor size of less than 3 cm is 1.75 times greater (21 months versus 12 months) than with a tumor size of more than 3 cm. The most significant morphological prognostic factor is the histological type of malignant tumor and the histological gradation of tumor tissue. Among carcinomas, the most invasive are micropapillary, solid and cribriform carcinomas, the most unaggressive is carcinoma in situ. Adverse prognostic factors of mammary cancer in cats are a high Ki67 index of proliferative activity, hyperexpression of Her-2 epidermal growth factor, cyclooxygenase-2, absence or low level of expression of receptors to estrogen and/or progesterone by tumor cells (less than 10%), as well as a high level of expression by tumor cells of VEGF (vascular endothelial growth factor).

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

1996 ◽  
Vol 14 (10) ◽  
pp. 2702-2708 ◽  
Author(s):  
C Carlomagno ◽  
F Perrone ◽  
C Gallo ◽  
M De Laurentiis ◽  
R Lauria ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Early Stage ◽  
Cox Model ◽  
Early Stage Breast Cancer ◽  
Adjuvant Tamoxifen ◽  
Independent Effect ◽  
Axillary Lymph ◽  
Breast Cancer Patients

PURPOSE We studied retrospectively the interaction between c-erbB2 overexpression and adjuvant tomoxifen in node-negative breast cancer patients enrolled in the Gruppo Universitario Napoletano 1 (GUN-1) trial. PATIENTS AND METHODS c-erbB2, evaluated by immunohistochemistry in 145 of 173 patients randomly assigned to 2-year adjuvant tamoxifen or no further therapy, was considered overexpressed if greater than 10% of the cells showed specific membrane staining. The role of each prognostic variable and their independent effect were studied using the Cox model. Disease-free (DFS) and overall (OAS) survival curves were estimated by the Kaplan-Meier method. RESULTS As of November 30, 1994, the median follow-up period was 12 years. c-erbB2 was overexpressed in 43 of 145 patients (29.7%), which directly correlated with tumor size and inversely with estrogen receptor (ER) level. At univariate analysis, overexpression of c-erbB2 did not affect either DFS or OAS; tamoxifen had a greater effect on reducing the risk of recurrence than of death. Addition of c-erbB2 to a multivariate Cox model that contained menopausal status, tumor size, nuclear grade, and treatment as covariates did not affect the significance of the model for DSF or OAS, whereas addition of the first-order interaction between c-erbB2 and tamoxifen was statistically significant both for DFS and OAS. The same result was obtained when the model contained ER status and ER-tamoxifen interaction. Indeed, adjuvant tamoxifen significantly prolonged DFS and OAS in c-erbB2-negative cases, whereas it had no effect on DFS and OAS in c-erbB2-positive patients. CONCLUSION In early-stage breast cancer patients, overexpression of c-erbB2 is a marker of lack of efficacy of adjuvant tamoxifen.

Correlation between change of FA score and postoperative recurrence in esophageal cancer patients who received neoadjuvant treatment.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 41-41
Author(s):  
Satoru Matsuda ◽  
Hiroya Takeuchi ◽  
Kazumasa Fukuda ◽  
Rieko Nakamura ◽  
Tsunehiro Takahashi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Univariate Analysis ◽  
Neoadjuvant Treatment ◽  
Postoperative Recurrence ◽  
Transthoracic Esophagectomy ◽  
Clinicopathological Factors ◽  
Significant Difference

41 Background: We previously reported that fibrinogen and albumin score (FA score), which was consisted of plasma fibrinogen level (FNG) and serum albumin level (Alb), was shown to predict postoperative survival in esophageal cancer patients who underwent transthoracic esophagectomy. In this study, in patients who received neoadjuvant chemotherapy (NAC), change of FA score during NAC was reviewed and the correlation with recurrence free survival (RFS) was investigated. Methods: We retrospectively reviewed 125 patients who received neoadjuvant chemotherapy and underwent transthoracic esophagectomy in our institution between 2001 and 2012. FNG and Alb before (preTx) and after (preope) NAC were confirmed in 92 patients. Based on our previous reports, patients with elevated fibrinogen ( > 350 mg/dL) and decreased albumin ( < 3.8 g/dl) levels were allocated a FA score of 2, those with only one of these abnormalities were allocated a FA score of 1, and those with neither of these abnormalities were allocated a FA score of 0. Regarding change of FA score, based on the preTx and preope FA score, we classified into decrease group and increase (no change or increase) group. Patient characteristics, clinicopathological factors, preTx FA score, and preope FA score were reviewed, and correlation with RFS was investigated. Results: The number of preTx and preope FA score 0/1/2 was 39/41/12, 36/37/19. Regarding change of FA score, FA score decreased in 70 patients (76%), increased in 22 (24%). There was no significant difference in patient background and clinicopathological factors between groups. In survival univariate analysis, change of FA score (Increase group, HR 2.023, p = 0.025) were significantly correlated with RFS. In multivariate analysis, using preTx clinical stage as a covariate, FA score was shown to be an independent predict factor (Increase group, HR 2.076, p = 0.023) for RFS significantly. Conclusions: Change of FA score between before and after NAC was shown to be a predictive factor of RFS in esophageal cancer patients who received NAC. Both fibrinogen and albumin are popular indicators routinely measured in daily clinical practice, FA score may be highly validate and feasible.

Sign in / Sign up

Export Citation Format

Share Document